Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension

BACKGROUND: In participants with pulmonary arterial hypertension, 24 weeks of sotatercept resulted in a significantly greater reduction from baseline in pulmonary vascular resistance than placebo. This report characterises the longer-term safety and efficacy of sotatercept in the PULSAR open-label e...

Descripción completa

Detalles Bibliográficos
Autores principales: Humbert, Marc, McLaughlin, Vallerie, Gibbs, J. Simon R., Gomberg-Maitland, Mardi, Hoeper, Marius M., Preston, Ioana R., Souza, Rogerio, Waxman, Aaron B., Ghofrani, Hossein-Ardeschir, Escribano Subias, Pilar, Feldman, Jeremy, Meyer, Gisela, Montani, David, Olsson, Karen M., Manimaran, Solaiappan, de Oliveira Pena, Janethe, Badesch, David B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816418/
https://www.ncbi.nlm.nih.gov/pubmed/36041750
http://dx.doi.org/10.1183/13993003.01347-2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816418/
https://www.ncbi.nlm.nih.gov/pubmed/36041750
http://dx.doi.org/10.1183/13993003.01347-2022

Ejemplares similares